Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 5:2:93.
doi: 10.3389/fmed.2015.00093. eCollection 2015.

Cord Blood as a Source of Natural Killer Cells

Rohtesh S Mehta  1 , Elizabeth J Shpall  2 , Katayoun Rezvani  2
Affiliations
Review

Cord Blood as a Source of Natural Killer Cells

Rohtesh S Mehta et al. Front Med (Lausanne). .

Abstract

Cord blood (CB) offers several unique advantages as a graft source for hematopoietic stem cell transplantation (HSCT). The risk of relapse and graft vs. host disease after cord blood transplantation (CBT) is lower than what is typically observed after other graft sources with a similar degree of human leukocyte antigen mismatch. Natural killer (NK) cells have a well-defined role in both innate and adaptive immunity and as the first lymphocytes to reconstitute after HSCT and CBT, and they play a significant role in protection against early relapse. In this article, we highlight the uses of CB NK cells in transplantation and adoptive immunotherapy. First, we will describe differences in the phenotype and functional characteristics of NK cells in CB as compared with peripheral blood. Then, we will review some of the obstacles we face in using resting CB NK cells for adoptive immunotherapy, and discuss methods to overcome them. We will review the current literature on killer-cell immunoglobulin-like receptors ligand mismatch and outcomes after CBT. Finally, we will touch on current strategies for the use of CB NK cells in cellular immunotherapy.

Keywords: CBT; KIR mismatch; adoptive immunotherapy; cord blood; natural killer cells; transplantation.

PubMed Disclaimer

References

    1. Pasquini MC, Zhu X. Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation: 2014 CIBMTR Summary Slides (2014). Available from: http://www.cibmtr.org
    1. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. Crit Rev Oncol Hematol (2011) 79(2):112–26.10.1016/j.critrevonc.2010.07.009 - DOI - PMC - PubMed
    1. Danby R, Rocha V. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol (2014) 5:68.10.3389/fimmu.2014.00068 - DOI - PMC - PubMed
    1. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 110(8):3064–70.10.1182/blood-2007-04-067215 - DOI - PMC - PubMed
    1. Rodrigues CA, Sanz G, Brunstein CG, Sanz J, Wagner JE, Renaud M, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol (2009) 27(2):256–63.10.1200/JCO.2007.15.8865 - DOI - PubMed

LinkOut - more resources